2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Apolipoprotein
  5. Apolipoprotein Isoform
  6. Apolipoprotein Inhibitor

Apolipoprotein Inhibitor

Apolipoprotein Inhibitors (7):

Cat. No. Product Name Effect Purity
  • HY-132820
    Inaxaplin
    		Inhibitor 99.44%
    Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease.
  • HY-147425A
    Zerlasiran sodium
    		Inhibitor
    Zerlasiran sodium is an apolipoprotein A (ApoA) synthesis reducer.
  • HY-169932
    APOL1-IN-2
    		Inhibitor
    APOL1-IN-2 (Compound 467) is the inhibitor for Apolipoprotein 1 (APOL1). APOL1-IN-2 reduces the APOL1 G2/G1 induced cell death in HEK293 with EC50 of 4.74 nM and 14.3 nM. APOL1-IN-2 reduces the APOL1 G2/G1/G0 induced death of trypanosomes with EC50 of 2.24, 6.03 and 3.72 nM, respectively.
  • HY-141885
    APOL1-IN-1
    		Inhibitor 99.85%
    APOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be used for the research of focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD).
  • HY-143200
    OSBPL7-IN-1
    		Inhibitor 99.79%
    OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression.
  • HY-147425
    Zerlasiran
    		Inhibitor
    Zerlasiran is an apolipoprotein A (ApoA) synthesis reducer.
  • HY-165061
    5(Z),11(Z),14(Z)-Eicosatrienoic acid
    		Inhibitor
    5(Z),11(Z),14(Z)-Eicosatrienoic acid (Sciadonic acid), a polyunsaturated fatty acid sourced from maritime pine seed oil, gymnospermae leaves and seeds, and freshwater gastropods, has been shown to reduce high-density lipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1 when included in their diet. In vitro studies indicate that it diminishes cholesterol efflux, and when applied topically in its methyl ester form, it alleviates inflammatory processes, likely by displacing arachidonic acid from phospholipid pools and lowering concentrations of downstream inflammatory mediators such as prostaglandin E2 and leukotrienes.